Fexinidazole

From WikiProjectMed
Jump to navigation Jump to search

Fexinidazole
Names
Other names
  • Fexinidazole Winthrop
  • HOE 239
  • 1-Methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole
Clinical data
Main usesAfrican trypanosomiasis (sleeping sickness) cause by Trypanosoma brucei gambiense[1]
Side effectsNausea, vomiting, headache, trouble sleeping[2]
Defined daily dose1.4 gram[3]
External links
AHFS/Drugs.comMonograph
Chemical and physical data
FormulaC12H13N3O3S
Molar mass279.31 g·mol−1
3D model (JSmol)
  • [O-][N+](=O)c1cnc(n1C)COc2ccc(SC)cc2

Fexinidazole is a medication used to treat African trypanosomiasis (sleeping sickness) cause by Trypanosoma brucei gambiense.[1] It is effective against both first and second stage disease.[1] Some evidence also supports its use in Chagas disease.[4] It is taken by mouth.[4]

Common side effects include nausea, vomiting, headache, and trouble sleeping.[2] Other side effects may include QT prolongation, psychosis, and low white blood cells.[5] It is unclear if use during pregnancy or breast feeding is safe.[5] Fexinidazole is in the antiparasitic and the nitroimidazole family of medications.[4] It is believed to work by turning on certain enzymes within the parasites that result in their death.[2]

Fexinidazole was first described in 1978.[6] It was given a positive opinion by the European Medicines Agency in 2018 and approved for medical use in the United States in 2021.[2][7] It is on the World Health Organization's List of Essential Medicines.[8] Development for sleeping sickness was funded by the Drugs for Neglected Diseases initiative in collaboration with Sanofi.[9]

Medical use

Sleeping sickness

A trial in Africa found fexinidazole to be 91% effective at treating sleeping sickness.[2][10] Though less effective than nifurtimox with eflornithine in severe disease, fexinidazole has the benefit that it can be taken by mouth.[2]

Fexinidazole is the first drug candidate for the treatment of advanced-stage sleeping sickness in thirty years.[11]

Other

It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica,[12] and Trypanosoma brucei.[13] It has not been found to be useful for visceral leishmaniasis.[4]

Dosage

The defined daily dose is 1.4 gram.[3]

Mechanism of action

The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.[14][15]

History

Timeline for fexinidazole.[16][17]

Fexinidazole was discovered by the German pharmaceutical company Hoechst AG, but its development as a pharmaceutical was halted in the 1980s.[18]

Society and culture

Fexinidazole Winthrop, a Sanofi-Aventis product developed with the Drugs for Neglected Diseases Initiative (DNDi), received a positive endorsement from the European Medicines Agency in 2018, for use in non-European markets.[19][20] It was approved for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the Democratic Republic of the Congo (DRC) in December 2018.[21]

References

  1. ↑ 1.0 1.1 1.2 DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency. Archived from the original on 18 January 2021. Retrieved 12 November 2019.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.
  3. ↑ 3.0 3.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 28 August 2021. Retrieved 10 September 2020.
  4. ↑ 4.0 4.1 4.2 4.3 Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.
  5. ↑ 5.0 5.1 "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.
  6. ↑ Gil, Carmen; Rivas, Luis (2017). Drug Discovery for Leishmaniasis. Royal Society of Chemistry. p. 30. ISBN 9781788012584. Archived from the original on 28 August 2021. Retrieved 12 November 2019.
  7. ↑ Research, Center for Drug Evaluation and (21 June 2022). "Novel Drug Approvals for 2021". FDA. Archived from the original on 3 March 2022. Retrieved 28 October 2022.
  8. ↑ "World Health Organization model list of essential medicines: 21st list 2019". 2019. hdl:10665/325771. {{cite journal}}: Cite journal requires |journal= (help)
  9. ↑ "Fexinidazole – DNDi". www.dndi.org. Archived from the original on 29 April 2020. Retrieved 12 November 2019.
  10. ↑ Mesu VK, Kalonji WM, Bardonneau C, et al. (4 November 2017). "Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial". Lancet. 391 (10116): 144–154. doi:10.1016/s0140-6736(17)32758-7. ISSN 0140-6736. PMID 29113731.
  11. ↑ Torreele, E; Bourdin Trunz, B; Tweats, D; Kaiser, M; Brun, R; Mazué, G; Bray, MA; Pécoul, B (2010). Boelaert, Marleen (ed.). "Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness". PLOS Neglected Tropical Diseases. 4 (12): e923. doi:10.1371/journal.pntd.0000923. PMC 3006138. PMID 21200426.
  12. ↑ Raether, W; Seidenath, H (1983). "The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica". Annals of Tropical Medicine and Parasitology. 77 (1): 13–26. PMID 6411009.
  13. ↑ Jennings, FW; Urquhart, GM (1983). "The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice". Zeitschrift für Parasitenkunde. 69 (5): 577–581. doi:10.1007/bf00926669. PMID 6636983.
  14. ↑ Wyllie S, Patterson S, Stojanovski L, et al. (2012). "The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis". Science Translational Medicine. 4 (119): 119re1. doi:10.1126/scitranslmed.3003326. PMC 3457684. PMID 22301556.
  15. ↑ Sokolova AY, Wyllie S, Patterson S, et al. (2010). "Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis". Antimicrobial Agents and Chemotherapy. 54 (7): 2893–900. doi:10.1128/AAC.00332-10. PMC 2897277. PMID 20439607.
  16. ↑ Imran, Mohd; Khan, Shah Alam; Alshammari, Mohammed Kanan; Alqahtani, Ashwaq Muiedh; Alanazi, Turkiah Abdullah; Kamal, Mehnaz; Jawaid, Talha; Ghoneim, Mohammed M.; Alshehri, Sultan; Shakeel, Faiyaz (21 January 2022). "Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis". Pharmaceuticals. 15 (2): 128. doi:10.3390/ph15020128. ISSN 1424-8247. Retrieved 12 September 2024.
  17. ↑ Probyn, Katrin; Buckley, Brian; Cogo, Elise; Bergman, Hanna; Petkovic, Jennifer; Sebastianski, Meghan; Sguassero, Yanina; Henschke, Nicholas; Villanueva, Gemma (February 2024). "Evidence summary: systematic review of oral fexinidazole as first line treatment for rhodesiense Human African Trypanosomiasis". Guidelines for the treatment of human African trypanosomiasis [Internet]. World Health Organization.
  18. ↑ McNeil, Jr., Donald (8 January 2008). "Jump-Start on Slow Trek to Treatment for a Disease". The New York Times. Archived from the original on 29 July 2020. Retrieved 21 February 2017.
  19. ↑ "CHMP Summary of Opinion - Fexinidazole Winthrop" (PDF). Archived (PDF) from the original on 24 December 2018. Retrieved 19 November 2018.
  20. ↑ McNeil, Jr., Donald (16 November 2018). "Rapid Cure Approved for Sleeping Sickness, a Horrific Illness". The New York Times. Archived from the original on 19 November 2018. Retrieved 20 November 2018.
  21. ↑ "Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo". Drugs for Neglected Diseases Initiative (DNDi). Archived from the original on 14 March 2020. Retrieved 4 June 2019.

External links

External sites:
Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Fexinidazole&oldid=1439151"